Recently, Shandong Benefit Mankind Glycobiologoy Biotechnology Co., Ltd. (hereinafter referred to as BMG), a supplier engaged in the research, development, production, and sale of nanoscale chitooligosaccharide products, announced the completion of a ten-million-yuan angel round of financing led by Zhonghe Capital. The funds from this round of financing will primarily be used for product research and development investment, concurrently accelerating market channel expansion to broaden the application of the company’s products in the end-market.
Founded in January 2020, BMG is a high-tech enterprise integrating production, academia, and research, equipped with cutting-edge international technology for chitooligosaccharide preparation. Its research primarily focuses on functional health foods, biopharmaceuticals, and medical devices. The company has overcome technical challenges in preparing active chitooligosaccharides and successfully developed nanoscale chitooligosaccharide products with high water solubility and biological activity, currently positioned at the forefront internationally.
Public information indicates that chitooligosaccharides are derived from materials such as shrimp and crab shells. Their activity varies with molecular weight, exhibiting functions that not only enhance immunity and regulate blood sugar but also eliminate human body oxygen free radicals, delay aging, and demonstrate exceptional moisturizing properties. With the increasing widespread application of chitooligosaccharides, particularly in fields like food, pharmaceuticals, and cosmetics, the potential market scope is vast.
BMG has stated that their future product directions include developing skincare products such as injectable gels and moisturizing masks that utilize chitosan’s moisture absorption, moisturizing, and antibacterial properties, as well as toothpaste aimed at inhibiting Helicobacter pylori.
It’s worth noting that both Dr. Zhao Yuexia from Ningxia Medical University General Hospital and Dr. Tai Weiping from Beijing Century Altar Hospital, affiliated with Capital Medical University, have publicly stated that currently, there is no toothpaste clinically proven to eradicate Helicobacter pylori. Treatment typically involves certain medications. Furthermore, according to the ‘Toothpaste Supervision and Management Measures,’ apart from efficacy claims falling within the allowed scope determined by the categorized directory, toothpaste labels should not explicitly or implicitly indicate medical effects, contain false or misleading information, or violate societal norms and ethics.
